List view / Grid view
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
Researchers have discovered a cross-reactive coronavirus antibody that could aid in the development of a broad-acting vaccine or treatment.
Researchers have shown that inhalable nanobodies at ultra-low doses can effectively neutralise SARS-CoV-2 in hamsters.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
A new modelling method could be used as a surveillance tool to monitor emerging infectious SARS-CoV-2 variants, scientists say.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
